ABL1 and cancer: One suchexample is the T315I mutation in the BCR-ABL kinase domain (threonineis substituted by isoleucine), which confers resistance against imatinib,a tyrosine kinase inhibitor used in treatment of BCR-ABL-positivehematological cancers.